Literature DB >> 2289207

Effects of bestatin on myelopoietic stem cells in normal and cyclophosphamide-treated mice.

F Abe1, A Matsuda, M Schneider, J E Talmadge.   

Abstract

The effect of bestatin on hematopoietic parameters and bone marrow progenitor activity (colony-forming unit - granulocyte/macrophage: CFU-GM) was examined in normal and myelosuppressed C57BL/6 mice. CFU-GM frequency and absolute number were determined with a limiting dilution analysis of bone marrow cells in soft agar using recombinant murine colony-stimulating factor - granulocyte/macrophage. We report that bestatin increased splenic, bone marrow, and peripheral blood cellularity and the number of CFU-GM over a dose range from 2.5 mg/kg through 100 mg/kg following i.p., i.v., or oral administration. The greatest myeloid stimulation was observed following multiple injections of bestatin. Bestatin also increased the recovery from cyclophosphamide-induced myelodepression as measured by these parameters. The hematopoietic properties of bestatin following oral administration is of potential importance for clinical application.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2289207     DOI: 10.1007/bf01754202

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  44 in total

1.  A phase I study of therapy with recombinant granulocyte-macrophage colony-stimulating factor administered by IV bolus or continuous infusion.

Authors:  R M Rifkin; E M Hersh; S E Salmon
Journal:  Behring Inst Mitt       Date:  1988-08

2.  Myelostimulatory activity of recombinant human interleukin-2 in mice.

Authors:  J E Talmadge; M Schneider; J Keller; F Ruscetti; D Longo; R Pennington; O Bowersox; H Tribble
Journal:  Blood       Date:  1989-05-01       Impact factor: 22.113

Review 3.  Clinical use of recombinant human hematopoietic growth factors.

Authors:  J Laver; M A Moore
Journal:  J Natl Cancer Inst       Date:  1989-09-20       Impact factor: 13.506

4.  Immunomodulatory and therapeutic properties of bestatin in mice.

Authors:  J E Talmadge; B F Lenz; R Pennington; C Long; H Phillips; M Schneider; H Tribble
Journal:  Cancer Res       Date:  1986-09       Impact factor: 12.701

5.  Pharmacokinetics of human granulocyte-macrophage colony-stimulating factor using a sensitive immunoassay.

Authors:  J Cebon; P Dempsey; R Fox; G Kannourakis; E Bonnem; A W Burgess; G Morstyn
Journal:  Blood       Date:  1988-10       Impact factor: 22.113

6.  Immunological and haematological monitoring in bladder cancer patients receiving adjuvant bestatin treatment following radiation therapy. A prospective randomized trial.

Authors:  H Blomgren; F Edsmyr; P L Esposti; I Näslund
Journal:  Biomed Pharmacother       Date:  1984       Impact factor: 6.529

7.  Ability of the immunomodulating dipeptide bestatin to activate cytotoxic mononuclear phagocytes.

Authors:  H U Schorlemmer; K Bosslet; H H Sedlacek
Journal:  Cancer Res       Date:  1983-09       Impact factor: 12.701

8.  Stimulation of cell-mediated immunity by bestatin correlates with reduction of bacterial persistence in experimental chronic Salmonella typhimurium infection.

Authors:  G Dickneite; F Kaspereit; H H Sedlacek
Journal:  Infect Immun       Date:  1984-04       Impact factor: 3.441

9.  Inhibition of lymph node metastasis of P388 leukemia by bestatin in mice.

Authors:  T Tsuruo; K Naganuma; H Iida; T Yamori; S Tsukagoshi; Y Sakurai
Journal:  J Antibiot (Tokyo)       Date:  1981-09       Impact factor: 2.649

10.  Enhancement of antitumor effect of cytotoxic agents by bestatin.

Authors:  F Abe; K Shibuya; J Ashizawa; K Takahashi; H Horinishi; A Matsuda; M Ishizuka; T Takeuchi; H Umezawa
Journal:  J Antibiot (Tokyo)       Date:  1985-03       Impact factor: 2.649

View more
  1 in total

1.  Inhibitory effect of the oral immune response modifier, bestatin, on cell-mediated and cell-free HIV infection in vitro.

Authors:  A S Bourinbaiar; S Lee-Huang; K Krasinski; W Borkowsky
Journal:  Biomed Pharmacother       Date:  1994       Impact factor: 6.529

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.